These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6751979)

  • 1. Effect of ketanserin, a new inhibitor of 5-HT2 receptors, on plasma renin activity and aldosterone levels in normal subject.
    Degli Uberti EC; Trasforini G; Margutti AR; Rotola CA; Pansini R
    Horm Res; 1982; 16(4):244-8. PubMed ID: 6751979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ketanserin, an inhibitor of 5-HT2 receptors, on the aldosterone-stimulating action of metoclopramide.
    Degli Uberti EC; Trasforini G; Margutti AR; Rotola CA; Bianconi M; Pansini P
    Horm Res; 1983; 17(3):160-7. PubMed ID: 6343215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ketanserin in primary aldosteronism.
    Mantero F; Rocco S; Opocher G; Armanini D; Boscaro M; D'Agostino D
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S172-5. PubMed ID: 2412045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.
    Zoccali C; Zabludowski JR; Isles CG; Murray GD; Inglis GC; Robertson JI; Fraser R; Ball SG
    Br J Clin Pharmacol; 1983 Sep; 16(3):305-11. PubMed ID: 6626423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses of the systemic circulation and of the renin-angiotensin-aldosterone system to ketanserin at rest and exercise in normal man.
    Fagard R; Cattaert A; Lijnen P; Staessen J; Vanhees L; Moerman E; Amery A
    Clin Sci (Lond); 1984 Jan; 66(1):17-25. PubMed ID: 6690191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral serotonin2 receptor blockade does not inhibit 5-hydroxytryptophan-induced aldosterone stimulation.
    Shenker Y; Gross MD; Grekin RJ
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1201-4. PubMed ID: 2932460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cisapride, a serotonin-4 receptor agonist, on aldosterone secretion: absence of age-related change.
    Huang YY; Hsu BR; Tsai JS
    J Clin Pharmacol; 1997 Dec; 37(12):1146-9. PubMed ID: 9506010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
    Zabludowski JR; Zoccali C; Isles CG; Murray GD; Robertson JI; Inglis GC; Fraser R; Ball SG
    Br J Clin Pharmacol; 1984 Mar; 17(3):309-16. PubMed ID: 6712863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists.
    Bagdy G; Sved AF; Murphy DL; Szemeredi K
    Eur J Pharmacol; 1992 Jan; 210(3):285-9. PubMed ID: 1535317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that the serotonin agonist, DOI, increases renin secretion and blood pressure through both central and peripheral 5-HT2 receptors.
    Rittenhouse PA; Bakkum EA; Van de Kar LD
    J Pharmacol Exp Ther; 1991 Oct; 259(1):58-65. PubMed ID: 1920135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ketanserin on cardiovascular, sympatho-adrenal and endocrine systems during physical exercise in man.
    Defer G; Guezennec CY; Fraitag B; Lhoste F
    Fundam Clin Pharmacol; 1987; 1(2):135-43. PubMed ID: 3315914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
    Wenting GJ; Man in 't Veld AJ; Woittiez AJ; Boomsma F; Schalekamp MA
    Br Med J (Clin Res Ed); 1982 Feb; 284(6315):537-9. PubMed ID: 6800533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of chronic ketanserin therapy on blood pressure and certain humoral and metabolic factors in patients with mild to moderate primary essential hypertension].
    Knypl K; Wocial B; Berent H; Kuçzyńska K; Wasowska T; Brym E; Czerniewska E; Wacławek-Maczkowska J; Januszewicz W
    Pol Arch Med Wewn; 1993 Aug; 90(2):95-104. PubMed ID: 8247951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.
    Wenting GJ; Woittiez AJ; Man in't Veld AJ; Schalekamp MA
    Hypertension; 1984; 6(1):100-9. PubMed ID: 6319278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ketanserin on peripheral vascular pressor mechanisms in essential hypertension.
    Elliott HL; Donnelly R; Reid JL
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S62-6. PubMed ID: 2459518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of angiotensin II and of an angiotensin II analogue (Sar1-Ile8-angiotensin II) on blood pressure, plasma aldosterone and plasma renin activity in the dog.
    Beckerhoff R; Uhlschmid G; Vetter W; Armbruster H; Nussberger J; Reck G; Schmied U; Siegenthaler W
    Clin Sci Mol Med Suppl; 1975 Jun; 2():41s-44s. PubMed ID: 1077788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of serotonin type 2 receptors in regulation of aldosterone production.
    Matsuoka H; Ishii M; Goto A; Sugimoto T
    Am J Physiol; 1985 Aug; 249(2 Pt 1):E234-8. PubMed ID: 2992285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sensitivity of human blood platelets to the aggregating agent ADP during different dietary sodium intakes in healthy men.
    Gow IF; Dockrell M; Edwards CR; Elder A; Grieve J; Kane G; Padfield PL; Waugh CJ; Williams BC
    Eur J Clin Pharmacol; 1992; 43(6):635-8. PubMed ID: 1493845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An experimental study on the effects of the chronic administration of an angiotensin converting enzyme inhibitor (captopril) on blood pressure and the renin-angiotensin-aldosterone system (author's transl)].
    Goto A
    Nihon Naibunpi Gakkai Zasshi; 1980 Jun; 56(6):868-83. PubMed ID: 6997093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.